Evidence map›Paper›PMID 33404277›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2021

Design, synthesis and evaluation of carbazole derivatives as potential antimicrobial agents.

Yi-Jie Xue, Ming-Yue Li, Xue-Jun Jin, Chang-Ji Zheng, Hu-Ri Piao

Abstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Synthesis of benzo[RSC advances · 2023
    Article
  8. Article
  9. Design and Synthesis of Novel Antimicrobial Agents.Antibiotics (Basel, Switzerland) · 2023
    Review
  10. Article
  11. Carbazole Derivatives as Potential Antimicrobial Agents.Molecules (Basel, Switzerland) · 2022
    Review
  12. Article
  13. Recent Developments in the Synthesis of β-Diketones.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  14. Development of Carbazole Derivatives Compounds againstJournal of fungi (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yi-Jie XueKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, China.
Ming-Yue LiKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, China.
Xue-Jun JinKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, China.
Chang-Ji ZhengKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, China.
Hu-Ri PiaoKey Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University, Yanji, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Five series of novel carbazole derivatives containing an aminoguanidine, dihydrotriazine, thiosemicarbazide, semicarbazide or isonicotinic moiety were designed, synthesised and evaluated for their antimicrobial activities. Most of the compounds exhibited potent inhibitory activities towards different bacterial strains (including one multidrug-resistant clinical isolate) and one fungal strain with minimum inhibitory concentrations (MICs) between 0.5 and 16 µg/ml. Compounds

Indexed as

Anti-Infective AgentsBacterial ProteinsBinding SitesCandida albicansCarbazolesCell LineCell Line, TumorEnzyme InhibitorsEpithelial CellsEscherichia coliGuanidinesHepatocytesHumansInhibitory Concentration 50Isonicotinic AcidsMethicillin-Resistant Staphylococcus aureusAnti-Infective AgentsBacterial ProteinsCarbazolesEnzyme InhibitorsGuanidinesIsonicotinic AcidspimagedineSemicarbazidesTetrahydrofolate DehydrogenasethiosemicarbazideTriazinesantibacterial activitiesantifungal activitiesCarbazolecytotoxicitystructure–activity relationship

Identifiers

PMID33404277
PMCPMC7801072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.